Compound 13
2-chloro-N-(2-(1-(1-(pentan-2-yl)piperidin-4-yl)-3-(3-(trifluoromethyl)phenyl)ureido)ethyl)acetamide
From: Blocking an N-terminal acetylation–dependent protein interaction inhibits an E3 ligase
Synthetic procedure: See article for the definitive version of this procedure and for full experimental details.
Average Purity (ELSD/UV): 95%. 1H NMR (500 MHz, Acetone-d6) δ 9.12 (s, 1H), 8.40 (bs, 1H), 8.34 (s, 1H), 7.97 (d, J = 8.3 Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.29 (d, J = 7.8 Hz, 1H), 4.49 – 4.30 (m, 1H), 4.26 (s, 2H), 3.44 (m, 4H), 3.25 – 3.10 (m, 2H), 3.03 (bs, 1H), 2.95 – 2.68 (m, 2H), 2.12 – 1.91 (m, 4H), 1.87 – 1.57 (m, 2H), 1.40 (m, 2H), 1.18 (d, J = 6.4 Hz, 3H), 0.94 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, Acetone-d6) δ 168.8, 154.8, 142.0, 130.1 (q, J = 31.7 Hz), 129.2, 124.6 (q, J = 271.5 Hz), 122.5, 117.9 (q, J = 4.0 Hz), 115.5 (q, J = 4.1 Hz), 59.9, 50.9, 49.3, 46.3, 42.1, 40.7, 40.0, 34.2, 19.5, 13.4, 13.0. LRMS (APCI+) m/z calcd for C22H33ClF3N4O2 [M+H]+ 477.2, found 477.2.
- PubChemID:
-
336287080
- MDL Molfile:
- ChemDraw:
